Clifford Swan Investment Counsel LLC Purchases 18,611 Shares of Pfizer Inc. (NYSE:PFE)

Clifford Swan Investment Counsel LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 417,070 shares of the biopharmaceutical company’s stock after acquiring an additional 18,611 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Pfizer were worth $12,007,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new position in Pfizer during the third quarter valued at about $30,000. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. bought a new position in Pfizer during the third quarter valued at about $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $36,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.4 %

NYSE:PFE traded up $0.11 during trading hours on Friday, hitting $27.81. 60,568,852 shares of the stock were exchanged, compared to its average volume of 41,900,304. The company’s 50 day moving average is $26.88 and its two-hundred day moving average is $28.16. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a price-to-earnings-growth ratio of 1.19 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Morgan Stanley upped their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.